Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study…
14,200€
0,71%
Echtzeit-Aktienkurs Theravance Biopharma
Bid:
Ask:
Nachrichten zur Theravance Biopharma Aktie
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
Investors need to pay close attention to TBPH stock based on the movements in the options market lately.…
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
…
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
…
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
…
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
…
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
…
Theravance Biopharma, Inc. 2023 Q4 - Results - Earnings Call Presentation
…